These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 911968)

  • 21. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
    Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
    Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
    Hasegawa R; Koizumi M; Hirose A
    Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer dose--response assessment for acrylonitrile based upon rodent brain tumor incidence: use of epidemiologic, mechanistic, and pharmacokinetic support for nonlinearity.
    Kirman CR; Gargas ML; Marsh GM; Strother DE; Klaunig JE; Collins JJ; Deskin R
    Regul Toxicol Pharmacol; 2005 Oct; 43(1):85-103. PubMed ID: 16099568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A simple method for quantitative risk assessment of non-threshold carcinogens based on the dose descriptor T25.
    Sanner T; Dybing E; Willems MI; Kroese ED
    Pharmacol Toxicol; 2001 Jun; 88(6):331-41. PubMed ID: 11453374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case study of cancer data set combinations for PCBs.
    Vater ST; Velazquez SF; Cogliano VJ
    Regul Toxicol Pharmacol; 1995 Aug; 22(1):2-10. PubMed ID: 7494898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonlinearity and thresholds in dose-response relationships for carcinogenicity due to sampling variation, logarithmic dose scaling, or small differences in individual susceptibility.
    Lutz WK; Gaylor DW; Conolly RB; Lutz RW
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):565-9. PubMed ID: 15982698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Approaches to the risk assessment of genotoxic carcinogens in food: a critical appraisal.
    O'Brien J; Renwick AG; Constable A; Dybing E; Müller DJ; Schlatter J; Slob W; Tueting W; van Benthem J; Williams GM; Wolfreys A
    Food Chem Toxicol; 2006 Oct; 44(10):1613-35. PubMed ID: 16887251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guidelines for the evaluation of chemicals for carcinogenicity. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment.
    Rep Health Soc Subj (Lond); 1991; 42():1-80. PubMed ID: 1763238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current and emerging challenges in toxicopathology: carcinogenic threshold of phenobarbital and proof of arsenic carcinogenicity using rat medium-term bioassays for carcinogens.
    Fukushima S; Morimura K; Wanibuchi H; Kinoshita A; Salim EI
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):225-9. PubMed ID: 15993454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Confidence intervals for the 50 per cent response dose.
    Faraggi D; Izikson P; Reiser B
    Stat Med; 2003 Jun; 22(12):1977-88. PubMed ID: 12802816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A search for thresholds and other nonlinearities in the relationship between hexavalent chromium and lung cancer.
    Park RM; Stayner LT
    Risk Anal; 2006 Feb; 26(1):79-88. PubMed ID: 16492182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward a molecular equivalent dose: use of the medaka model in comparative risk assessment.
    Hobbie KR; Deangelo AB; King LC; Winn RN; Law JM
    Comp Biochem Physiol C Toxicol Pharmacol; 2009 Mar; 149(2):141-51. PubMed ID: 18722551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uncertainty estimates for low-dose-rate extrapolations of animal carcinogenicity data.
    Guess H; Crump K; Peto R
    Cancer Res; 1977 Oct; 37(10):3475-83. PubMed ID: 908002
    [No Abstract]   [Full Text] [Related]  

  • 34. A dose-response test via closed-form solutions for constrained MLEs in survival/sacrifice experiments.
    Kim W; Ahn H; Moon H
    Stat Med; 2007 Feb; 26(3):694-708. PubMed ID: 16596576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of alternative methods for establishing safe levels of occupational exposure to vinyl halides.
    Storm JE; Rozman KK
    Regul Toxicol Pharmacol; 1997 Jun; 25(3):240-55. PubMed ID: 9237327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs.
    Gardner SN
    Cancer Res; 2000 Mar; 60(5):1417-25. PubMed ID: 10728708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Methods of risk assessment from data of experimental carcinogenesis studies].
    Roller M; Csicsaky M; Pott F
    Zentralbl Hyg Umweltmed; 1992 Mar; 192(6):479-93. PubMed ID: 1315551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence-based dose-response assessment for thyroid tumorigenesis from acrylamide.
    Dourson M; Hertzberg R; Allen B; Haber L; Parker A; Kroner O; Maier A; Kohrman M
    Regul Toxicol Pharmacol; 2008 Dec; 52(3):264-89. PubMed ID: 18775759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calculation of carcinogenic potency from long-term animal carcinogenesis experiments.
    Sawyer C; Peto R; Bernstein L; Pike MC
    Biometrics; 1984 Mar; 40(1):27-40. PubMed ID: 6733232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Order-restricted dose-related trend tests.
    Mancuso JY; Ahn H; Chen JJ
    Stat Med; 2001 Aug; 20(15):2305-18. PubMed ID: 11468765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.